ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $3.31 | N/A |
Market Cap | $77.88M | N/A |
Shares Outstanding | 23.56M | -0.19% |
Employees | 0 | N/A |
Shareholder Equity | 523.39K | 44.37% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -11.94 | N/A |
P/B Ratio | 148.79 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -9.1506 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$4.79M | N/A |
EPS | -0.2767 | N/A |
Earnings Yield | -0.0837 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $493.49K | N/A |
Cash on Hand | $475.34K | N/A |
Debt to Equity | 0.2084 | 190.77% |
Current Ratio | $4.52 | -59.79% |